Jeet Mukherjee
Stock Analyst at BTIG
(3.91)
# 635
Out of 5,115 analysts
25
Total ratings
56%
Success rate
13.35%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeet Mukherjee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRIX Nurix Therapeutics | Reiterates: Buy | $30 | $16.52 | +81.60% | 5 | Jan 29, 2026 | |
| PVLA Palvella Therapeutics | Reiterates: Buy | $192 | $76.80 | +150.00% | 4 | Jan 29, 2026 | |
| KYMR Kymera Therapeutics | Reiterates: Buy | $138 | $72.69 | +89.85% | 4 | Jan 15, 2026 | |
| MNPR Monopar Therapeutics | Reiterates: Buy | $104 | $60.38 | +72.24% | 4 | Jan 14, 2026 | |
| CATX Perspective Therapeutics | Reiterates: Buy | $14 | $3.79 | +269.39% | 3 | Jan 13, 2026 | |
| BCAX Bicara Therapeutics | Initiates: Buy | $28 | $16.80 | +66.67% | 1 | Jan 8, 2026 | |
| FHTX Foghorn Therapeutics | Initiates: Buy | $11 | $5.71 | +92.64% | 1 | Dec 18, 2025 | |
| AARD Aardvark Therapeutics | Initiates: Buy | $26 | $12.99 | +100.15% | 1 | Nov 7, 2025 | |
| ARVN Arvinas | Maintains: Buy | $10 → $14 | $13.38 | +4.63% | 2 | Oct 30, 2025 |
Nurix Therapeutics
Jan 29, 2026
Reiterates: Buy
Price Target: $30
Current: $16.52
Upside: +81.60%
Palvella Therapeutics
Jan 29, 2026
Reiterates: Buy
Price Target: $192
Current: $76.80
Upside: +150.00%
Kymera Therapeutics
Jan 15, 2026
Reiterates: Buy
Price Target: $138
Current: $72.69
Upside: +89.85%
Monopar Therapeutics
Jan 14, 2026
Reiterates: Buy
Price Target: $104
Current: $60.38
Upside: +72.24%
Perspective Therapeutics
Jan 13, 2026
Reiterates: Buy
Price Target: $14
Current: $3.79
Upside: +269.39%
Bicara Therapeutics
Jan 8, 2026
Initiates: Buy
Price Target: $28
Current: $16.80
Upside: +66.67%
Foghorn Therapeutics
Dec 18, 2025
Initiates: Buy
Price Target: $11
Current: $5.71
Upside: +92.64%
Aardvark Therapeutics
Nov 7, 2025
Initiates: Buy
Price Target: $26
Current: $12.99
Upside: +100.15%
Arvinas
Oct 30, 2025
Maintains: Buy
Price Target: $10 → $14
Current: $13.38
Upside: +4.63%